Jazz Pharmaceuticals plc
JAZZ
$229.63
$0.440.19%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 4.44B | 4.27B | 4.16B | 4.09B | 4.06B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.44B | 4.27B | 4.16B | 4.09B | 4.06B |
| Cost of Revenue | 454.67M | 432.77M | 410.77M | 393.50M | 387.13M |
| Gross Profit | 3.98B | 3.83B | 3.75B | 3.69B | 3.68B |
| SG&A Expenses | 1.51B | 1.67B | 1.65B | 1.60B | 1.58B |
| Depreciation & Amortization | 672.51M | 654.61M | 643.77M | 632.86M | 625.98M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.39B | 3.50B | 3.48B | 3.40B | 3.40B |
| Operating Income | 1.05B | 768.62M | 675.54M | 684.24M | 664.72M |
| Income Before Tax | -219.04M | -628.54M | -703.75M | -512.22M | 361.34M |
| Income Tax Expenses | -248.53M | -272.43M | -335.31M | -107.42M | -120.90M |
| Earnings from Continuing Operations | 29.49 | -356.11 | -368.44 | -404.80 | 482.24 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 29.49M | -356.11M | -368.44M | -404.80M | 482.24M |
| EBIT | 1.05B | 768.62M | 675.54M | 684.24M | 664.72M |
| EBITDA | 1.76B | 1.46B | 1.36B | 1.36B | 1.33B |
| EPS Basic | 0.47 | -5.78 | -5.96 | -6.60 | 7.82 |
| Normalized Basic EPS | 10.07 | 5.85 | 4.79 | 4.74 | 4.38 |
| EPS Diluted | -0.02 | -5.97 | -6.07 | -6.73 | 7.50 |
| Normalized Diluted EPS | 9.72 | 5.71 | 4.73 | 4.66 | 4.16 |
| Average Basic Shares Outstanding | 244.85M | 243.95M | 243.43M | 244.15M | 245.83M |
| Average Diluted Shares Outstanding | 252.33M | 247.23M | 245.30M | 246.87M | 255.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |